Literature DB >> 32934047

Non-alcoholic fatty liver disease.

Wenhao Li1, William Alazawi2.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. NAFLD is defined by excess fat in the liver and has a multidirectional relationship with metabolic syndrome. The prevalence of NAFLD has risen rapidly in recent years in line with the obesity epidemic and associated increases in type 2 diabetes, hypertension and hypercholesterolaemia. Patients with NAFLD are at risk of cardiovascular disease and cancer, and in a proportion of individuals, NAFLD is associated with liver damage. This article summarises the epidemiology of NAFLD, the clinical approach to risk-assessing patients and briefly outlines current and future management options. © Royal College of Physicians 2020. All rights reserved.

Entities:  

Keywords:  Non-alcoholic fatty liver disease; cirrhosis; fibrosis; non-alcoholic steatohepatitis

Mesh:

Year:  2020        PMID: 32934047      PMCID: PMC7539730          DOI: 10.7861/clinmed.2020-0696

Source DB:  PubMed          Journal:  Clin Med (Lond)        ISSN: 1470-2118            Impact factor:   2.659


  22 in total

1.  Prospective evaluation of a primary care referral pathway for patients with non-alcoholic fatty liver disease.

Authors:  Ankur Srivastava; Ruth Gailer; Sudeep Tanwar; Paul Trembling; Julie Parkes; Alison Rodger; Deepak Suri; Douglas Thorburn; Karen Sennett; Sarah Morgan; Emmanuel A Tsochatzis; William Rosenberg
Journal:  J Hepatol       Date:  2019-04-06       Impact factor: 25.083

Review 2.  Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus.

Authors:  Fernando Bril; Kenneth Cusi
Journal:  Endocrinol Metab Clin North Am       Date:  2016-10-04       Impact factor: 4.741

3.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Authors:  Arun J Sanyal; Naga Chalasani; Kris V Kowdley; Arthur McCullough; Anna Mae Diehl; Nathan M Bass; Brent A Neuschwander-Tetri; Joel E Lavine; James Tonascia; Aynur Unalp; Mark Van Natta; Jeanne Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck
Journal:  N Engl J Med       Date:  2010-04-28       Impact factor: 91.245

4.  Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.

Authors:  Eduardo Vilar-Gomez; Yadina Martinez-Perez; Luis Calzadilla-Bertot; Ana Torres-Gonzalez; Bienvenido Gra-Oramas; Licet Gonzalez-Fabian; Scott L Friedman; Moises Diago; Manuel Romero-Gomez
Journal:  Gastroenterology       Date:  2015-04-10       Impact factor: 22.682

5.  Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

Authors:  Christopher D Williams; Joel Stengel; Michael I Asike; Dawn M Torres; Janet Shaw; Maricela Contreras; Cristy L Landt; Stephen A Harrison
Journal:  Gastroenterology       Date:  2010-09-19       Impact factor: 22.682

6.  Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.

Authors:  Paul Angulo; Elisabetta Bugianesi; Einar S Bjornsson; Phunchai Charatcharoenwitthaya; Peter R Mills; Francisco Barrera; Svanhildur Haflidadottir; Christopher P Day; Jacob George
Journal:  Gastroenterology       Date:  2013-07-13       Impact factor: 22.682

7.  FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest.

Authors:  Anaïs Vallet-Pichard; Vincent Mallet; Bertrand Nalpas; Virginie Verkarre; Antoine Nalpas; Valérie Dhalluin-Venier; Hélène Fontaine; Stanislas Pol
Journal:  Hepatology       Date:  2007-07       Impact factor: 17.425

8.  Guidelines on the management of abnormal liver blood tests.

Authors:  Philip N Newsome; Rob Cramb; Suzanne M Davison; John F Dillon; Mark Foulerton; Edmund M Godfrey; Richard Hall; Ulrike Harrower; Mark Hudson; Andrew Langford; Anne Mackie; Robert Mitchell-Thain; Karen Sennett; Nicholas C Sheron; Julia Verne; Martine Walmsley; Andrew Yeoman
Journal:  Gut       Date:  2017-11-09       Impact factor: 23.059

9.  Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.

Authors:  Myriam Alexander; A Katrina Loomis; Johan van der Lei; Talita Duarte-Salles; Daniel Prieto-Alhambra; David Ansell; Alessandro Pasqua; Francesco Lapi; Peter Rijnbeek; Mees Mosseveld; Dawn M Waterworth; Stuart Kendrick; Naveed Sattar; William Alazawi
Journal:  BMC Med       Date:  2019-05-20       Impact factor: 8.775

10.  Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

Authors:  Matthew James Armstrong; Piers Gaunt; Guruprasad P Aithal; Darren Barton; Diana Hull; Richard Parker; Jonathan M Hazlehurst; Kathy Guo; George Abouda; Mark A Aldersley; Deborah Stocken; Stephen C Gough; Jeremy W Tomlinson; Rachel M Brown; Stefan G Hübscher; Philip N Newsome
Journal:  Lancet       Date:  2015-11-20       Impact factor: 79.321

View more
  3 in total

1.  Protective Effect of Danshen Zexie Decoction Against Non-Alcoholic Fatty Liver Disease Through Inhibition of ROS/NLRP3/IL-1β Pathway by Nrf2 Signaling Activation.

Authors:  Yaning Biao; Jian Chen; Chenxu Liu; Ruilong Wang; Xue Han; Li Li; Yixin Zhang
Journal:  Front Pharmacol       Date:  2022-06-21       Impact factor: 5.988

Review 2.  Epidemiology of Alcohol-Associated Liver Disease.

Authors:  Sen Han; Zhihong Yang; Ting Zhang; Jing Ma; Kristina Chandler; Suthat Liangpunsakul
Journal:  Clin Liver Dis       Date:  2021-05-26       Impact factor: 6.265

3.  The contribution of daytime sleepiness to impaired quality of life in NAFLD in an ethnically diverse population.

Authors:  Wenhao Li; Benjamin Karl Kadler; James Hallimond Brindley; Gillian Hood; Kalpana Devalia; John Loy; Wing-Kin Syn; William Alazawi
Journal:  Sci Rep       Date:  2022-03-24       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.